On October 6, 2020, FDA hosted a public meeting on Patient-Focused Drug Development for Stimulant Use Disorder. FDA was interested in obtaining patient perspectives on the health effects and daily impacts of stimulant use disorder, impact (if any) of opioid and polysubstance use on stimulant use disorder, treatment goals, and decision factors considered when seeking out or selecting a treatment. For more information, visit the meeting webpage.